Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Cash & Equivalents: 2019-2025

Historic Cash & Equivalents for Allogene Therapeutics (ALLO) over the last 7 years, with Sep 2025 value amounting to $37.8 million.

  • Allogene Therapeutics' Cash & Equivalents fell 26.20% to $37.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $37.8 million, marking a year-over-year decrease of 26.20%. This contributed to the annual value of $75.2 million for FY2024, which is 9.54% down from last year.
  • As of Q3 2025, Allogene Therapeutics' Cash & Equivalents stood at $37.8 million, which was down 27.74% from $52.3 million recorded in Q2 2025.
  • In the past 5 years, Allogene Therapeutics' Cash & Equivalents registered a high of $236.9 million during Q1 2021, and its lowest value of $37.8 million during Q3 2025.
  • Its 3-year average for Cash & Equivalents is $81.6 million, with a median of $69.2 million in 2023.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first spiked by 74.30% in 2021, then tumbled by 69.34% in 2025.
  • Over the past 5 years, Allogene Therapeutics' Cash & Equivalents (Quarterly) stood at $173.3 million in 2021, then slumped by 64.28% to $61.9 million in 2022, then skyrocketed by 34.33% to $83.2 million in 2023, then decreased by 9.54% to $75.2 million in 2024, then fell by 26.20% to $37.8 million in 2025.
  • Its last three reported values are $37.8 million in Q3 2025, $52.3 million for Q2 2025, and $42.5 million during Q1 2025.